Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ironwood PharmaceuticalsSTU:I76 +0.54%74 3-Year ROIIC % is 147.68 as of Dec. 2025, which is 379% above its 10-year median of 30.81. GuruFocus rates STU:I76 with a GF Score™ of 74/100 and a GF Value™ of €3.85 (Fairly Valued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Ironwood Pharmaceuticals ranks better than 92.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ironwood Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 147.68%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ironwood Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
STU:I76's 3-Year ROIIC % is ranked better than 92.79% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs STU:I76: 147.68
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ironwood Pharmaceuticals 3-Year ROIIC % Related Terms
Ironwood Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:I76 vs TLRY, AQST, ELTP: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's 3-Year ROIIC % falls into.
Ironwood Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 34.78706 (Dec. 2025) - 163.886533 (Dec. 2022) )
/
( 296.986 (Dec. 2025) - 413.218 (Dec. 2022) )
=
-129.099473
/
-116.232
=
111.07%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ironwood Pharmaceuticals (STU:I76) has a 3-Year ROIIC % of 147.68 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ironwood Pharmaceuticals and its competitors. This is 379% above median its historical median of 30.81. According to the industry distribution chart, Ironwood Pharmaceuticals ranks #68 out of 943 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is Ironwood Pharmaceuticals' 3-Year ROIIC % too high?
Ironwood Pharmaceuticals' current 3-Year ROIIC % of 147.68 is 379% above median its 10-year median of 30.81. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Ironwood Pharmaceuticals' value of 147.68 is 4048.3% above this industry median. Based on the distribution chart, Ironwood Pharmaceuticals ranks #68 out of 943 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ironwood Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ironwood Pharmaceuticals' 3-Year ROIIC % compare to TLRY and AQST?
According to the Drug Manufacturers industry distribution chart, Ironwood Pharmaceuticals ranks #68 out of 943 companies for 3-Year ROIIC %. This places Ironwood Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.56. Ironwood Pharmaceuticals' value of 147.68 is 4048.3% above this benchmark. While the company's 10-year median is 30.81 vs. the industry median of 3.56, Ironwood Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ironwood Pharmaceuticals's current 3-Year ROIIC % of 147.68 is 4048.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ironwood Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ironwood Pharmaceuticals's current 3-Year ROIIC % is 147.68, which is 379% above median its own 10-year median of 30.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ironwood Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals (STU:I76) is currently considered Fairly Valued. The stock's GF Value™ is €3.85, compared to a current price of €3.70 — trading 3.9% below its estimated fair value. The current 3-Year ROIIC % is 147.68, which is 379% above median its 10-year median of 30.81 and 4048.3% above the Drug Manufacturers industry median of 3.56. Ironwood Pharmaceuticals' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ironwood Pharmaceuticals (STU:I76), the current 3-Year ROIIC % is 147.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ironwood Pharmaceuticals (STU:I76) Overvalued in 2026?
Based on GuruFocus' analysis, Ironwood Pharmaceuticals stock appears to be undervalued.
The current stock price of €3.70 is trading 3.9% below its estimated GF Value™ of €3.85.
GuruFocus considers Ironwood Pharmaceuticals to be Fairly Valued.
Key valuation signals for STU:I76:
3-Year ROIIC %: 147.68 (379% above median its 10-year median of 30.81)
GF Value™: €3.85 vs. price of €3.70 (3.9% below fair value)
Industry Position: 4048.3% above the Drug Manufacturers median (#68 of 943)
No single metric tells the full story. See the STU:I76 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
74GF Score
Get the complete analysis for STU:I76
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:I76 has been successfully added to your 
